Entweder 10000% oder Totalverlust
Warum ich nicht einsteige? Nun, ich bin nicht von diesem Unternehmen überzeugt. Ich vermisse das Produkt, das so einzigartig ist, daß es jeder benötigt.
Sind wir doch einmal ehrlich: Warum rennt man diesem Unternehmen nicht die Bude ein, wenn dieser Test so toll ist? Warum nur CHina, wo doch jeder, der sich etwas mit Pharma auskennt weiß, daß man in Amerika den Durchbruch schaffen muß (und dabei ist das Unternehmen doch in Kalifornien beheimatet)?
Also, mich reißt halt ein kleiner Auftrag aus China nicht von Hocker. Außerdem habe ich mir mal die Bilanzen angesehen, da liegt einiges im Argen (aber das weißt DU ja sicher).
Zum Risiko: Gehe ich immer ein, aber nur, wenn ich von etwas überzeugt bin. Allerdings halte ich nicht nur Risikopositionen.
Wenn DU es genau wissen willst, denke ich immer nur an die Rendite, die ich erwirtschaften werde. Deshalb besteht mein Depot auch aus einer Mischung starker Dividendentitel, langfristigen ANlagen mit einem zeithorizont von über 10 Jahren, und Turnaround-Spekulationen über einen Zeitraum von 2-3 Jahren.
Das sieht dann so aus:
Dividendentitel:
Pilip Morris
Eni
Enel
Turnaround etablierter Unternehmen:
DaimlerChrysler
spekulativer Turnaround:
Lucent
Ericsson
langfristige Anlage wegen Wachstumsaussichten:
Centrotec
Zapf Creation
Biju Brigitte
Fondsbeimischung:
DWS Vermögensbildung I
Templeton Growth
2 Rentenfonds (DWS und ABN Amro)
Geldmarktfonds (Commerzbank)
Zertifikat:
Endloszertifikat der Deutschen Bank auf S&P
So long,
Calexa
www.investorweb.de
mom hier die meldung vom 19.09.2002
Calypte Biomedical Corp. (ticker: CALY, exchange: NASDAQ) News Release - 19-Sep-2002
--------------------------------------------------
Calypte's Urine HIV-1 Antibody Test Now Approved for Life Insurance Screening In All 50 States
ALAMEDA, Calif., Sep 19, 2002 /PRNewswire-FirstCall via COMTEX/ --
West Virginia Department of Insurance Amends Rule to Include Urine HIV-1 Antibody Testing
Calypte Biomedical Corporation (OTC Bulletin Board: CALY), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, announced today that the West Virginia Office of the Insurance Commissioner has cleared the way for urine HIV screening among life insurance applicants in that state. With this decision, Calypte's urine HIV-1 screening test is now approved for use by the life insurance industry in all 50 states.
Until now, life and health insurance companies writing policies in West Virginia have been unable to test specimens other than blood and oral fluid for HIV. The Interpretive Rule amendment made by the commissioner is intended to serve as a bridge to the effective date of the Legislative Rule, and allows the urine-based screening to begin immediately. The Legislative Rule is expected to be effective in the spring or summer of 2003.
"Life Insurance companies have been very receptive to urine-based testing as an effective, convenient and cost-effective alternative to blood testing," said Nancy Katz, President and CEO of Calypte Biomedical. "We now have the approval of approximately 150 insurance companies to order our tests, including nine of the top 10 life insurance underwriters as ranked by policy value. The Calypte urine antibody tests are completely non-invasive, which results in a painless and comfortable way for insurance applicants to provide a specimen. Also, urine testing is safe for those collecting the specimen who otherwise would be at risk of contracting HIV from accidental needlestick injuries. We are very pleased that the State of West Virginia has made progress developing the necessary procedures that allow our life insurance customers to expand their utilization of urine testing."
"Now that West Virginia has joined every other state in approving urine screening tests for HIV-1 antibodies, we believe that it will be even easier to get our message out to life insurance and other communities that our proprietary urine screening test represents the future direction of HIV-1 screening," said Anthony Cataldo, Calypte's Chairman.
About Calypte Biomedical:
Calypte Biomedical Corporation headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. When compared with existing blood-based tests, our testing algorithms are non-invasive, easier to use, less expensive and have significantly less risk than blood-based testing, and they have 99.7% sensitivity in subjects previously identified as HIV-1 infected and 100% specificity in subjects at low risk when combined with the urine-based Western Blot supplemental test. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2001 and its subsequent filings with the SEC.
For further information, please contact Joe Bunning of Sitrick and Company, +1-310-788-2850, for Calypte Biomedical Corporation.
SOURCE Calypte Biomedical Corporation
CONTACT: Joe Bunning of Sitrick and Company, +1-310-788-2850, for Calypte Biomedical Corporation
News provided by COMTEX. User agreement applies
See 1997 Press Releases See 1998 Press Releases See 1999 Press Releases
P.s
dein depot finde ich überrings sehr gut, das einzigste was mich ein wenig stören würde ist ( Ericsson ) meinst wirklich die gehen wieder ?
DWS I ist auch mein haubtbestandteil ca 40%
Grüße von
Letztendlich zählt nur das Geld, daß netto als Gewinn in den Büchern steht. Und das ist Calypte-Biomedical noch weit von entfernt.
Das ist ja auch nur meine Meinung. Das Problem bei solchen Werten ist, daß man durch Glück sicherlich ziemlich schnell einige % machen kann. ABer 10 $ sind wohl doch nur Utopie, zumindest noch den momentanen Meldungen. Ne,ne, für mich müssen da erst noch ein paar mehr Geschäftsabschlüsse her.
Außerdem: Nehmen wir mal an, daß Calypte abgeht wir eine Rakete, und sagen wir auch mal, daß sie auf 5 $ gehen. Und jetzt nehmen wir an, bei ca 85 Millionen AKtien soll ein (meiner Meinung nach viel zu hohes, aber gestehen wir einen Bewertungsaufschlag dazu) KGV von 50 erreicht werden. Wie hoch muß dann der Gewinn sein???? 0,1 $ pro Aktie, also 8,5 Millionen $ netto. Bißchen viel meiner Meinung nach für eine Zusicherung und einen kleinen Auftrag nach China.
Ja, wenn jetzt regelmäßig Folgeaufträge kommen, dann sieht die Sache schon ganz anders aus. Aber ich kann ja warten. Selbst wenn ich erst bei 1 $ einsteige, hätte ich zu 10 $ einen Gewinn von 900%. Nicht schlecht, würde ich sagen....
Zu Ericsson:
Nun, ob die wieder groß werden ist die falsche Frage, denn die sind immer noch groß. So hat Ericsson die meisten Patente für die zukünftigen 2.5G und 3G-Netze. Außerdem melden die auch im Wochentakt neue Verträge.
Der Vergleich mit Nokia hat shon immer gehinkt, da Nokia sein Geld nun mal mit Handys, Ericsson aber mit Netzausrüstung macht. Außerdem haben die von Ericsson momentan genug Geld, um die nächsten 2 Jahre zu überstehen. Warten wir einfach mal die Zahlen am Freitag ab, dann wissen wir mehr.
SO long,
Calexa
Haben schlieslich auch 2 schei.. jahre hinter uns.( ich zumindest Thiel,Kontron,D-Logistics)
gruß grenke
p.s hoffe aber trozdem das du bei caly unrecht behälst( hihihi)
Sicherlich ist der 1. Auftrag mit lediglich 100.000 Tests relativ klein - jedoch stehen wir hier wirklich erst am Anfang.
Ich sagte, das ich ca. 6-8 Wochen nach meinem Einstieg abwarten werde ob irgendwelche Aufträge eingehen !
Spätestens seit heute bin ich mir sicher, das CALY wirklich der Knaller werden wird.
Ob die 10 $ erreicht werden, stelle ich jedoch in Frage.
Fakt ist jedoch, das ein Auftrag mit 100.000 Tests in einem so großen Land wie China geradezu verpufft und noch einiges an Potential zulässt.
In China leben immerhin mehrere Milliarden Menschen!!
Zudem ist Afrika ein weiterer potentieller Abnehmer und natürlich die USA auch.
Wir werden sicherlich noch viel Freude mit CALY haben.
Es ist jedoch etwas Geduld angesagt, dennoch sollten in den nächsten Wochen weitere positive Meldungen kommen.
Hier noch die Meldung von heute:
Calypte Biomedical Corp. (ticker: CALY, exchange: NASDAQ) News Release
- 15-Oct-2002
--------------------------------------------------
Calypte Receives First Commercial Order in China With New Distributor; Order for 100,000 Tests to Ship in Fourth Quarter 2002
ALAMEDA, Calif., Oct 15, 2002 (BUSINESS WIRE) -- Calypte Biomedical Corporation (OTCBB:CALY), the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced that it has received its first commercial order from its new Chinese distributor for the Urine HIV-1 EIA. Calypte has signed an exclusive two-year distribution agreement with Zhong Yang Pute Co. ("ZYPute"), a distributor of medical products in China.
The agreement calls for minimum purchase orders of Calypte's products, which are expected to add at least $3 million in revenue over the next two years. The company will begin manufacturing the first order of over 100,000 tests imminently, with shipping expected to occur in the fourth quarter. The agreement is automatically extendable for an additional two years contingent upon the distributor's performance and new minimum purchases will be negotiated at that time.
The agreement gives exclusive rights to distribute the Urine HIV-1 EIA and Urine HIV-1 Western Blot tests to specific market segments within 20 of the 31 Chinese provinces and to the military nationwide, along with non-exclusive distribution rights for the Serum HIV-1 Western Blot tests in the same territories. Calypte's Urine EIA test has been approved for distribution by the Chinese State Drug Administration (SDA) to customers that do not require lot release testing.
"Traditional blood testing is expensive, difficult to handle, poses potential risk hazards and can be culturally unacceptable in some parts of the world," stated Anthony Cataldo, executive chairman of Calypte. "Our tests provide a safe, non-invasive and cost-effective alternative with none of the risks associated with blood testing. The agreement with ZYPute is another example of Calypte's execution of acheivement milestones. We expect our products to play a major role in China's fight against HIV/AIDS. The agreement does not include our revolutionary Rapid Urine Test, which is anticipated to have a much larger market in China and the rest of the world than the current EIA."
According to a recent report by the United Nations, China could have more than 10 million HIV cases by 2010. China's health ministry has confirmed over one million cases and a 16% year-over-year increase in the number of people infected. China is now estimated to have Asia's fourth largest number of people infected with HIV/AIDS. Dr. Luc Montagnier, co-discoverer of HIV-1 and consultant to Calypte, visited with the Chinese government in August 2002 to discuss the increase in the need for continued mass screening for HIV. During the visit, he demonstrated the advantages of urine-based screening and promoted the Calypte product.
Nancy Katz, president and CEO of Calypte, stated, "We have been focused on gaining access to the Chinese market and securing distribution through a commercial distributor. Our choice in ZYPute stemmed from their steadfast belief that the minimum purchase requirements will be exceeded over the term of the agreement. Calypte stands to gain sizeable volume orders from this relationship and we look forward to a long and productive relationship with ZYPute. "
Katz added, "Already ZYPute has identified commercial applications for our Urine HIV EIA with the current level of SDA approval. We continue to pursue approval by the Biologics division of the SDA by early 2003, which will enable Calypte to sell tests to those customers that do require specific lot testing."
About Zhong Yang Bio-Medi-Tech (ZYPute):
ZYPute was previously one of 17 affiliates organized under the corporate umbrella of Beijing Pharmaceutical Co., a conglomerate with US$70 million in assets, and 3 publicly traded companies. ZYPute merged with HuaXin International Economic & Trade Co. Ltd., a company owned and operated by the Ministry of Foreign Trade and Economic Cooperation. Together, the companies have established 3 regional offices that will manage a network of 10 experienced sub-distributors, operating in 20 provinces. The union of the two companies gives ZYPute exceptional insight into the procurement processes of several markets in China that Calypte believes to be important consumers of HIV testing products, and the ability to communicate with policy-makers at levels that are normally not accessible to regional sub-distributors.
Although ZYPute was initially established as a distributor of aircraft supplies, primarily to the military, the company is now focused exclusively in the medical field. Its core medical business includes a range of hospital products in the field of infant nutrition.
Habe welche in Berlin zu 0,12 bekommen. Verspreche mir nicht zuviel davon, aber riskieren kann man ja mal 'nen paar Euro. Denke aber, hier wird man viel Zeit mitbringen müssen.
Grüße von
MfG X 99
Das sind immerhin rund 100.000 DM - da ist jemand echt überzeugt von dem Laden.
Gruß
AUF GEHT`S
Über 7 Mio gehandelt, das gefällt mir.
Ich erwarte allerdings morgen einen kleinen Rücksetzer bis max. 0,10$
CALY ist seit dem Tiefstand von 0,08 immerhin binnen 2 Tagen um 50% gestiegen.
Go,go,go...
AUF GEHT`S
MfG X 99
MfG X 99